Balaxi Pharmaceuticals Share Price

Balaxi Pharmaceuticals Investment Rating

• Master Rating:

• Balaxi Pharmaceuticals has an operating revenue of Rs. 279.39 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 20% is great, ROE of 42% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 9% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.